ApoPharma

What ApoPharma does

ApoPharma is a Toronto, Canada-based pharmaceutical company founded in 2004 that operates in the rare-disease therapeutics space. The company's core disclosed asset is EPI-743, an investigational pipeline therapy being developed for the treatment of ataxia, a neurological disorder characterized by impaired muscle control and coordination. ApoPharma is referenced in DelveInsight's 2026 ataxia therapeutics market report as one of eight key companies developing treatments in the seven major markets (7MM), with the ataxia therapeutics market projected to expand materially through 2034.

The company's product portfolio is narrow and pre-commercial: EPI-743 is described as a promising candidate still in development, with no disclosed FDA approvals, clinical trial milestones, partnership agreements, or commercialization timeline in the available data. The business model cannot be determined from current sources — there is no pricing information, no distribution channel disclosure, no revenue figure, no headcount, and no management team information. No technology stack, AI capabilities, or proprietary platform architecture is described.

ApoPharma's operating status is inferred to be active based on the continued reference to its pipeline asset, but the data set is materially thin. The relationship between ApoPharma and Apotex (a separate, much larger Canadian pharmaceutical company trading on the TSX as APTX) is not confirmed by available sources; ownership, parent-subsidiary status, and capital structure all remain undisclosed. The company's revenue model, GTM strategy, and customer base are not characterized, consistent with an early-stage or pre-revenue development-stage biotech.

Name

ApoPharma

Website

https://apopharma.com

Company type

Private

Founded year

2004

Operating status

Operating

Short description

ApoPharma is a Toronto-based pharmaceutical company developing EPI-743, an investigational pipeline therapy for ataxia, a rare neurological disorder. The company targets patients with ataxia and operates as a private, pre-commercial rare-disease biotech.

Ownership category

akta.pro rank

Product category

Rare Disease Therapeutics

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

akta.pro secondary industry

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

Keywords

• Rare disease therapeutics
• Ataxia treatment pipeline
• Neurological disorder therapy
• Investigational pharmaceutical
• Specialty pharmaceuticals

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Core offering

ApoPharma is a Toronto-based pharmaceutical company developing therapeutic solutions for rare neurological diseases. Its primary pipeline asset is EPI-743, an investigational therapy in development for the treatment of ataxia, a rare neurological disorder affecting movement and coordination. The company is positioned among key developers in the ataxia therapeutics market.

Product overview

ApoPharma is a pharmaceutical company focused on developing therapeutics for rare diseases, specifically mentioned in the ataxia therapeutics market. The company has a pipeline therapy called EPI-743 noted as a promising candidate in development for ataxia treatment.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves1 record

Expansion highlights1 record

Direct peers

• PTC Therapeutics: PTC Therapeutics acquired BioElectron, which originated EPI-743 (vatiquinone) — the same molecule ApoPharma lists in its pipeline. PTC is a direct peer as the most direct comparator for ApoPharma's lead asset in rare neurology.
• Minoryx Therapeutics: Minoryx is developing leriglitazone for X-linked adrenoleukodystrophy and Friedreich's ataxia. It is a direct peer as a European rare-neurology developer with overlapping ataxia indication targets.
• Larimar Therapeutics: Larimar's lead program (CTI-1601 / nomlabofusp) targets Friedreich's ataxia, the same indication ApoPharma's EPI-743 is pursuing. It is a direct peer as a small-cap ataxia-focused developer with a single-asset pipeline.
• Reata Pharmaceuticals: Reata developed Skyclarys (omaveloxolone), the first FDA-approved therapy for Friedreich's ataxia, a hereditary ataxia. It is a direct peer of ApoPharma because both companies compete in the ataxia therapeutics pipeline targeting the same rare-neurology patient population.
• Design Therapeutics: Design Therapeutics is developing a GeneTAC small-molecule candidate for Friedreich's ataxia. It is directly comparable to ApoPharma as another small, single-asset, rare-neurology focused drug developer targeting ataxia.

Broad incumbents

• BioMarin Pharmaceutical: BioMarin is an established rare-disease biopharmaceutical company with multiple approved therapies. It is a broad incumbent because it operates in the same orphan-disease commercial infrastructure that ApoPharma would need to access.
• Takeda Pharmaceutical: Takeda is a global rare-disease leader (post-Shire acquisition) with deep neurology and rare-disease commercial reach. It is a broad incumbent defining the competitive and partnership landscape ApoPharma operates in.
• Pfizer: Pfizer operates a broad rare-disease franchise and has multiple programs in neurological disorders. It is a broad incumbent whose commercial scale and pipeline breadth set the competitive ceiling in the rare-neurology segment.

Emerging players

• Lexeo Therapeutics: Lexeo develops AAV-mediated gene therapies for genetic neurological and cardiac diseases, including Friedreich's ataxia. It is an emerging peer whose ataxia program competes for the same patient pool as ApoPharma.
• Voyager Therapeutics: Voyager develops AAV-based gene therapies for severe neurological diseases including Friedreich's ataxia. It is an emerging peer because it competes in the ataxia therapeutics space via a different modality (gene therapy).

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/apopharma

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ApoPharma